Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-28), Precision BioSciences's 3-1 Month Momentum % is 3.55%.
The industry rank for Precision BioSciences's 3-1 Month Momentum % or its related term are showing as below:
DTIL's 3-1 Month Momentum % is ranked better than 71.89% of 1384
companies
in the Biotechnology industry
Industry Median: -11.005
vs DTIL: 3.55
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Precision BioSciences 3-1 Month Momentum % Related Terms
DTIL vs NERV, VYGR, GLSI: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Precision BioSciences's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Precision BioSciences 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Precision BioSciences's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Precision BioSciences's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Precision BioSciences (DTIL) has a 3-1 Month Momentum % of 3.55% as of Jul. 28, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Precision BioSciences and its competitors. According to the industry distribution chart, Precision BioSciences ranks #389 out of 1384 companies in the Biotechnology industry, placing it in the top 28.1%.
Is Precision BioSciences' 3-1 Month Momentum % too high?
Precision BioSciences' current 3-1 Month Momentum % is 3.55%. Based on the distribution chart, Precision BioSciences ranks #389 out of 1384 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Precision BioSciences has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Precision BioSciences' 3-1 Month Momentum % compare to NERV and VYGR?
According to the Biotechnology industry distribution chart, Precision BioSciences ranks #389 out of 1384 companies for 3-1 Month Momentum %. This puts Precision BioSciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Precision BioSciences and its competitors. Precision BioSciences's current 3-1 Month Momentum % is 3.55%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Precision BioSciences stock overvalued right now?
Based on GuruFocus' analysis, Precision BioSciences (DTIL) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.81, compared to a current price of $7.16 — trading 295.6% above its estimated fair value. The current 3-1 Month Momentum % is 3.55%. Precision BioSciences' overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Precision BioSciences (DTIL), the current 3-1 Month Momentum % is 3.55% as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Precision BioSciences (DTIL) Overvalued in 2026?
Based on GuruFocus' analysis, Precision BioSciences stock appears to be overvalued.
The current stock price of $7.16 is trading 295.6% above its estimated GF Value™ of $1.81.
GuruFocus considers Precision BioSciences to be Significantly Overvalued.
Key valuation signals for DTIL:
3-1 Month Momentum %: 3.55%
GF Value™: $1.81 vs. price of $7.16 (295.6% above fair value)
No single metric tells the full story. See the DTIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
50GF Score
Get the complete analysis for DTIL
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DTIL has been successfully added to your 
